Group 1: Company Performance - 24 innovative drug companies reported their 2025 performance, with 19 achieving positive net profit, representing 79.17% [1] - BeiGene achieved its first annual profit in 2025 with a net profit of 1.422 billion yuan, and total revenue of 38.205 billion yuan, a 40.4% increase year-on-year [1] - Microbio achieved a total revenue of 910 million yuan in 2025, a 38.24% increase, and a net profit of 51.0757 million yuan, marking a turnaround [2] - Shanghai Yizhong reported a revenue of 317 million yuan, an 82.72% increase, and a net profit of 64.132 million yuan, a significant 819.42% increase [2] Group 2: Industry Trends - The overall performance of the innovative drug industry is improving, but significant differentiation exists, with many companies still in a loss-reduction phase [1] - The continuous release of policy dividends is a key driver for performance growth, with nearly 80% of innovative drugs entering the medical insurance directory within two years [2] - The global healthcare industry saw a financing amount of 63.882 billion USD in 2025, a 10.13% increase, while domestic financing in the healthcare sector reached 73.777 billion yuan, a 39.05% increase [3] - The number of new drug IND applications in China reached 2,175 in 2025, an 8.8% increase [3]

Core Viewpoint - The new National Medical Insurance Drug List will be officially implemented on January 1, 2026, expanding the inclusion of innovative drugs while removing 29 drugs from the list, raising concerns among patients about potential increased costs and reduced insurance coverage [1][3]. Summary by Relevant Sections Drug List Adjustments - The National Medical Insurance Bureau has adjusted the drug list for eight consecutive years, with a total of 467 drugs removed to date [1]. - The updated list includes 3,253 drugs, with 114 new additions primarily targeting cancer, mental health, and pediatric medications [1]. Reasons for Drug Removals - Among the 29 drugs removed, there are 21 Western medicines and 8 traditional Chinese medicines, many of which have alternative options available in the insurance list [3]. - The reasons for removal can be categorized into three main types: 1. Strong clinical substitutability, with many drugs having more effective and safer alternatives [3]. 2. Low reimbursement rates, with 15 of the removed drugs having less than 0.01% reimbursement from the insurance fund in 2024, indicating minimal patient benefit [3]. 3. Low cost-effectiveness, where some drugs, despite being effective, are priced higher than similar alternatives without offering additional benefits [3]. Impact of New Additions - The inclusion of 114 new drugs enhances the choices available to clinicians and patients, better meeting patient needs, especially with the increased speed and quantity of innovative drugs being added [4]. - Although the inclusion of innovative drugs may exert some pressure on the insurance fund, management tools such as total budget control and reasonable drug use management are in place to mitigate significant impacts on the fund [4]. Patient Guidance - Patients are advised to follow the guidance of healthcare professionals regarding medication adjustments and should not self-medicate, as all drugs in the insurance list are prescription medications [5].

Core Insights - China has established a dynamic adjustment mechanism for the medical insurance catalog, focusing on newly launched drugs within the last five years [1] - The number of class 1 innovative drugs approved in China has significantly increased, reaching 48 in 2024, which is over five times the number in 2018 [1] - The inclusion of new drugs in the medical insurance catalog has accelerated the market entry of innovative drugs, with 114 new drugs added in 2025, many of which were approved and included in the catalog in the same year [1] Industry Trends - The stable return expectations from R&D investments are encouraging pharmaceutical companies to increase their innovation efforts, particularly in areas with unmet clinical needs such as oncology and rare diseases [1] - A pharmaceutical company has successfully included seven innovative drugs in the national basic medical insurance catalog this year [1] - The time from drug approval to inclusion in the medical insurance catalog has decreased from approximately five years to about one year, with around 80% of innovative drugs being included within two years of market launch [1] Market Dynamics - The medical insurance access has become a key factor for pharmaceutical companies' market expansion, allowing innovative drugs to rapidly gain market share while less clinically valuable drugs are removed from the catalog [1] - The total number of drugs in the national medical insurance catalog reached 3,253 by 2025, with class 1 innovative drugs increasing to 50 [1]

Group 1 - The dynamic adjustment mechanism for the medical insurance catalog in China has been established, focusing on new drugs launched within the last five years [1] - In 2025, 114 new drugs will be included in the medical insurance catalog, with several achieving approval and inclusion in the same year [1] Group 2 - Increased R&D investment returns are expected to encourage pharmaceutical companies to enhance innovation, particularly in areas with unmet clinical needs such as cancer and rare diseases [3] - Since 2018, the number of approved Class 1 innovative drugs has significantly increased, reaching 48 in 2024, which is over five times the number in 2018 [4] - The medical insurance catalog has become an "accelerator" for the rapid market entry of innovative drugs, contributing to the continuous expansion of China's innovative drug market [4] Group 3 - The time from drug approval to inclusion in the medical insurance catalog has decreased from approximately five years to about one year, with around 80% of innovative drugs being included within two years of market launch [6] - Medical insurance access has become crucial for pharmaceutical companies' market expansion, allowing innovative drugs to quickly gain market share while less valuable drugs are removed from the catalog [6] - As of 2025, the total number of drugs in the national medical insurance catalog has reached 3,253, with Class 1 innovative drugs increasing to 50 [6]

Core Viewpoint - During the "14th Five-Year Plan" period, China's medical insurance system has made significant progress in addressing urgent issues faced by the public, enhancing accessibility and affordability of medical services and medications [1][17]. Group 1: Medical Insurance Achievements - The implementation of centralized bulk purchasing and dynamic adjustments to the medical insurance drug list has enabled patients to access affordable medications and new treatments [1][5]. - The number of people benefiting from cross-provincial direct settlement of medical expenses has surged from 5.37 million in 2020 to 238 million in 2024, marking a 44-fold increase [13]. - The total expenditure of the medical insurance fund reached 12.13 trillion yuan during the "14th Five-Year Plan," with an average annual growth rate of 9.1% [15]. Group 2: Impact on Patients - The introduction of centralized procurement for high-value medical consumables, such as cochlear implants, has significantly reduced costs, with prices dropping from over 200,000 yuan to around 50,000 yuan [3][5]. - Innovative drugs, such as the newly approved treatment for rare lung cancer, have been included in the medical insurance directory, reducing patient costs from full out-of-pocket expenses to minimal payments after insurance coverage [9][11]. - The medical insurance coverage has expanded to include outpatient treatments for chronic diseases, providing greater financial relief for patients [11][13]. Group 3: Future Directions - The 11th batch of centralized procurement is underway, focusing on optimizing measures to ensure quality and affordability while promoting fair competition among pharmaceutical companies [7][9]. - The continuous improvement of the medical insurance system aims to enhance the accessibility and quality of healthcare services, ultimately contributing to the development of a healthier society [17].

Core Viewpoint - The National Healthcare Security Administration (NHSA) has introduced measures to support the high-quality development of innovative drugs, focusing on enhancing research support, facilitating access to insurance, and encouraging clinical application [1][2]. Summary by Relevant Sections Support for Innovative Drug Development - The NHSA has outlined 16 measures across five key areas to bolster innovative drug development, including support for research, inclusion in insurance directories, and enhancing payment capabilities [1][2]. - Approximately 80% of innovative drugs can be included in the insurance payment scope within two years of market launch [2]. Dynamic Adjustment Mechanism - A dynamic adjustment mechanism for the insurance directory has been established, reducing the adjustment cycle from a maximum of 8 years to 1 year, allowing for a more responsive inclusion of new drugs [2]. - The proportion of new drugs approved within five years that are included in the insurance directory has increased from 32% in 2019 to an expected 98% in 2024 [2]. Negotiation and Renewal Rules - The NHSA has improved negotiation and renewal rules for innovative drugs, focusing on patient clinical benefits to determine pricing [3]. - The number of first-class innovative drugs approved has significantly increased, with 48 new approvals expected in 2024, marking a fivefold increase since 2018 [3]. Encouragement of True Innovation - The measures emphasize the importance of supporting genuine and differentiated innovation in the pharmaceutical industry, addressing challenges such as homogenization and unclear clinical value [4][5]. - Since 2018, 149 innovative drugs have been included in the insurance directory, with total fund expenditures reaching 4.1 trillion yuan, driving significant sales growth [4]. Global Market Development - The NHSA aims to facilitate the global market expansion of innovative drugs, with over 90 overseas licensing transactions completed by Chinese pharmaceutical companies in 2024, totaling over $50 billion [7]. - The measures include building platforms for overseas market access and encouraging commercial health insurance to invest in innovative drugs [7][8]. Clinical Application and Usage - The NHSA encourages timely access to innovative drugs in designated medical institutions and supports the establishment of green channels for procurement [9]. - Measures have been introduced to enhance the capacity of medical institutions to use innovative drugs effectively, including optimizing payment standards and supporting special case applications [10].